Clinical Trials in Austin

Showing 2041-2060 of 7,312 trials

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630

This is a 73-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe plaque psoriasis. Ten (10) subjects will receive 200 mg of RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the end of the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.

Psoriasis

Janssen Research & Development, LLC8 participantsStarted Sep 2011

Owensboro, Kentucky, United States • Ann Arbor, Michigan, United States • Austin, Texas, United States

COMPLETEDPhase 1< 1 mile

Staccato Prochlorperazine Single Dose PK Study

NCT00610727

The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine

Migraine

Alexza Pharmaceuticals, Inc.54 participantsStarted Aug 2004

Austin, Texas, United States

COMPLETEDPhase 262 miles

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease. The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these patients.

Heart Failure With Preserved Ejection Fraction

Actelion143 participantsStarted Jul 2017

Phoenix, Arizona, United States • Beverly Hills, California, United States • San Diego, California, United States +92 more locations

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Staccato Prochlorperazine Single Dose PK Study

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Find Trials by Condition in Austin

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke